What To Expect From The ESMO ECC Cancer Meeting
This article was originally published in Scrip
Executive Summary
Clinical data for Roche AG's entrant to the PD-1/L1 immuno-oncology fray, atezolizumab, look set to dominate at the ESMO ECC2015 meeting in Vienna later this week.